Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from anti-C5 antibody to iptacopan in adults with aHUS
jRCT2031230686Recruiting
- Sponsor
- Novartis
- Start
- Mar 2024
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of Iptacopan in atypical hemolytic uremic syndrome (aHUS), sponsored by Novartis. Primary endpoint: Percentage of participants free of TMA manifestation at 12 months. Started Mar 2024; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on jRCT2031230686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230686.